Liberum acts as Nominated Adviser, Broker and Sole Bookrunner on the AIM IPO of SourceBio International plc raising £35m

SourceBio International plc (“SourceBio”) is a leading international provider of integrated state-of-the-art laboratory services and products in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. The Company employs approximately 235 employees across six sites globally, in the UK, Ireland and the USA with headquarters in Nottingham, UK.

On Admission, the market capitalisation of the Company was approximately £120 million.

The Placing attracted strong support from high quality institutional investors and was significantly over-subscribed.

The net proceeds of the Placing will be used to repay outstanding shareholder and bank loans and for general corporate expenses, including working capital and capital expenditure required in order to further scale-up the COVID-19 testing business, as well as pursue appropriate acquisitions.

The three main shareholders prior to the IPO, Harwood, Continental and Lombard Odier, have all retained a substantial shareholding in the Company, with Harwood and Lombard Odier also participating in the Placing.

Liberum acted as Nominated Adviser, Broker and Sole Bookrunner on the IPO, and is retained as NOMAD and Sole Broker to the Company post Admission.

Liberum Team

Investment Banking – Bidhi Bhoma, Joshua Hughes, Euan Brown, William Hall, Miquela Bezuidenhoudt, Anthony Schia

Board – David Parsons

Sales – Oliver Baxendale, Alistair Smallwood, Jamie Vickers, Julian Collett, Seb Fernandez

Research – Graham Doyle, Fowey Harvey, Alistair Campbell

Legal – Rebecca Gordon, Alice Foster

CIR – Natalie Clarke

Settlement – Rob Simpson, Mark Proctor

Sales Trading – Mark O’Hara